Keiko Tanimura

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

Hirokazu Taniguchi, Tadaaki Yamada, Rong Wang et al. · Nature Communications · 2019 · 363 citations · Full text

Medicine, Oncology, Pharmacology +17

The Proline-rich Akt Substrate of 40 kDa (PRAS40) Is a Physiological Substrate of Mammalian Target of Rapamycin Complex 1

Noriko Oshiro, Rinako Takahashi, Kenichi Yoshino et al. · Journal of Biological Chemistry · 2007 · 322 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +13

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer

Tadaaki Yamada, Soichi Hirai, Yuki Katayama et al. · Cancer Medicine · 2019 · 117 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer

Naoko Okura, Naoya Nishioka, Tadaaki Yamada et al. · Clinical Cancer Research · 2020 · 113 citations

Medicine, Oncology, Pharmacology +17

Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer

Naoya Nishioka, Junji Uchino, Soichi Hirai et al. · Journal of Clinical Medicine · 2019 · 90 citations · Full text

Medicine, Immunology, Oncology +17